Mayne Pharma Group Ltd Market Cap ($146.02 Million)
Market Cap & Net Worth: Mayne Pharma Group Ltd (MYX)
Mayne Pharma Group Ltd market cap. Mayne Pharma Group Ltd (AU:MYX) has a market capitalization of $146.02 Million (AU$206.36 Million) as of November 1, 2026. Listed on the AU stock exchange, this Australia-based company holds position #17578 globally and #514 in its home market, demonstrating a 2.01% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mayne Pharma Group Ltd's stock price AU$2.54 by its total outstanding shares 81245827 (81.25 Million). Also see how efficiently does Mayne Pharma Group Ltd generate cash for how efficiently the company converts equity into cash flow.
Mayne Pharma Group Ltd Market Cap History (2015–2026)
Mayne Pharma Group Ltd market cap history from 2015 to 2026. Data shows change from $1.53 Billion to $146.02 Million (-16.76% CAGR). Check current stock price of Mayne Pharma Group Ltd for real-time trading data and today's change.
Index Memberships
Mayne Pharma Group Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Australia All Ordinaries
AORD
|
$2.01 Trillion | 0.01% | #292 of 495 |
|
S&P/ASX 300
AXKO
|
$2.16 Trillion | 0.01% | #256 of 300 |
|
ASX Small Ordinaries
AXSO
|
$284.01 Billion | 0.05% | #164 of 200 |
Weight: Mayne Pharma Group Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mayne Pharma Group Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mayne Pharma Group Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Mayne Pharma Group Ltd equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.44x
Mayne Pharma Group Ltd's market cap is 0.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.54 Billion | $267.28 Million | $37.35 Million | 5.75x | 41.15x |
| 2017 | $794.23 Million | $572.60 Million | $88.57 Million | 1.39x | 8.97x |
| 2018 | $885.66 Million | $530.31 Million | -$133.98 Million | 1.67x | N/A |
| 2019 | $497.11 Million | $525.21 Million | -$279.20 Million | 0.95x | N/A |
| 2020 | $394.26 Million | $456.99 Million | -$92.79 Million | 0.86x | N/A |
| 2021 | $337.12 Million | $400.78 Million | -$208.42 Million | 0.84x | N/A |
| 2022 | $228.56 Million | $157.15 Million | -$281.29 Million | 1.45x | N/A |
| 2023 | $353.54 Million | $183.59 Million | $117.25 Million | 1.93x | 3.02x |
| 2024 | $285.71 Million | $388.15 Million | -$174.23 Million | 0.74x | N/A |
| 2025 | $178.78 Million | $408.10 Million | -$93.84 Million | 0.44x | N/A |
Competitor Companies of MYX by Market Capitalization
Companies near Mayne Pharma Group Ltd in the global market cap rankings as of November 1, 2026. Also see MYX current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Mayne Pharma Group Ltd by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #248 globally with a market cap of $101.38 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #451 globally with a market cap of $61.32 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #626 globally with a market cap of $43.01 Billion USD.
- Sigma Healthcare Ltd (AU:SIG): Ranked #1151 globally with a market cap of $22.30 Billion USD ( AU$31.51 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #248 | McKesson Corporation | NYSE:MCK | $101.38 Billion | $994.58 |
| #451 | Cencora Inc. | NYSE:COR | $61.32 Billion | $330.84 |
| #626 | Cardinal Health Inc | NYSE:CAH | $43.01 Billion | $250.48 |
| #1151 | Sigma Healthcare Ltd | AU:SIG | $22.30 Billion | AU$2.73 |
Market Capitalization of Mayne Pharma Group Ltd (2015–2026)
Market capitalization of Mayne Pharma Group Ltd from 2015 to today. Between 2015 and today, Mayne Pharma Group Ltd's market cap moved from $1.53 Billion to $ 146.02 Million, with a yearly change of -16.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$146.02 Million | -18.33% |
| 2025 | AU$178.78 Million | -37.42% |
| 2024 | AU$285.71 Million | -19.19% |
| 2023 | AU$353.54 Million | +54.69% |
| 2022 | AU$228.56 Million | -32.20% |
| 2021 | AU$337.12 Million | -14.49% |
| 2020 | AU$394.26 Million | -20.69% |
| 2019 | AU$497.11 Million | -43.87% |
| 2018 | AU$885.66 Million | +11.51% |
| 2017 | AU$794.23 Million | -48.33% |
| 2016 | AU$1.54 Billion | +0.48% |
| 2015 | AU$1.53 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Mayne Pharma Group Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $146.02 Million USD |
| MoneyControl | $146.02 Million USD |
| MarketWatch | $146.02 Million USD |
| marketcap.company | $146.02 Million USD |
| Reuters | $146.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mayne Pharma Group Ltd
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more